Colorectal Cancer

Biopharmaceutical company reports cancer therapy progress

Published in Cancer Weekly, July 22nd, 2003

Immunomedics, Inc., (IMMU) announced that four presentations made at an annual meeting of nuclear medicine physicians and scientists indicated progress in the development and use of antibody-based therapeutics for cancer therapy, particularly colorectal cancers.

Pretargeting methods involve the separation of antibody-based tumor targeting from the delivery of the therapeutic agent, using bispecific antibodies that bind to both the tumor and the carrier of the therapeutic agent, which is usually a peptide carrying a therapeutic isotope. This allows a rapid uptake of the radiolabeled peptide into the tumor, which results in significantly improved tumor...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-07-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry